

RECEIPT

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Daluge, et al

Docket No.

PB1517US3


Serial No.
08/957,045

Filing Date
10/24/97

Examiner
M. BERCH

Group Art Unit
1611

Invention: CHLOROPYRIMIDINE INTERMEDIATES



I hereby certify that this **REQUEST FOR CORRECTED FILING RECEIPT**
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The
Assistant Commissioner for Patents, Washington, D.C. 20231 on AUGUST 5, 1998
(Date)

Keysha Bishop

(Typed or Printed Name of Person Mailing Correspondence)

Keysha Bishop
(Signature of Person Mailing Correspondence)

RECEIVED

SEP 03 1998

MATERIALS CENTER
SERVICE CENTER

GlaxoWellcome

Keysha Bishop
Patent Document Specialist

August 5, 1998



Application Processing Division
Customer Correction Branch
Assistant Commissioner of Patents
Washington D.C. 20231

RECEIVED

SEP 03 1998

MATHIX CUSTOMER
SERVICE CENTER

To Whom It May Concern:

I am under the impression that the attached Request for Corrected Filing Receipt was never received by the Customer Correction Branch since I have not received a postcard receipt for this case. I wish to resubmit the request for corrected filing receipt for PB1517US3, serial no. 08/957,045 included is a copy of the most recent filing receipt I have received. To reiterate what is stated in the request for corrected filing receipt, Michelle Fugett should be deleted as an inventor and there are 5 total claims and 5 independent claims. Please see the attached documents for further information.

Feel free to contact me for any reason that may arise.

Thank you,

Keysha Bishop
Keysha Bishop

Phone: 919-483-1304
Fax: 919-483-7988
Email: keb8764@glaxowellcome.com

Glaxo Wellcome Inc.

Five Moore Drive
PO Box 13398
Research Triangle Park
North Carolina 27709

Telephone
919 248 2100



postcard not
received

DOCKET NO.: PB1517US3
SERIAL NO.: 08/957, 045

TITLE: chloropyrimidine Intermediates

The date stamp of the Patent Office hereon may be considered as the date on which papers indicated below are received.

- Application _____ pages _____ claims
 Abstract
 Assignment w/Coverletter
 Drawings (_____ sheets)
 Declaration/Oath w/Power of Attorney Unexecuted Executed
 Fee Authorization & Deposit Account Copy
 IDS-Publication Disclosure (37 CFR 1.56) w/o References w/References
 Amendment (_____)
 Petition for Extension of Time 1mo 2mo 3mo 4mo
 Issue Fee Transmittal
 Notice of Appeal
 Appeal Brief
 Req. for Oral Hearing
 Certificate of Mailing Express Mail 1st Class
 Request Corrected Filing Receipt

Mailed 5/13/98


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Daluge, et al.

Serial No.: 08/957,045

Filed: October 24, 1997

For: CHLOROPYRIMIDINE INTERMEDIATES



Art Unit: 1611

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

2. There is an error with respect to the following data, which is:

incorrectly entered

and/or

omitted.

Error in

1. Applicant's name
2. Applicant's address
3. Title
4. Filing Date
5. Serial Number
6. Foreign/PCT Application Re:
7. Other(s): CLAIMS

Correct data

1. Delete - Michelle Fugett
2. Delete - Durham, NC
- 3.
- 4.
- 5.
- 6.
7. TOT CL - 5; IND CL - 5

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8)

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Date: 5/13/98

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.

Keysha Bishop
Signature
Keysha Bishop

3.


- A. The correction(s) is/are not due to any error by applicant and no fee is due.

OR

B. At least one of the above corrections is due to applicant's error and the fee therefore, under 37 CFR 1.19(h), of \$25.00 is paid as follows:

- Enclosed is a check for \$25.00
 Charge Account 07-1392 \$25.00




Karen L. Prus
Reg. No.: 39,337

Date: May 12 1998

Glaxo Wellcome Inc.

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709

Phone: 919-483-1304

fax: 919-483-7988

RECEIVED

MAY - 1 1998

GLAXO WELLCOME
I.P. DEPT.

LOGGED IN

5/1/98 Keb

CPL/KLP/KCL/file

COPIED TO THE UK

PTO-103X
(Rev. 7-93)CORRECTED
FILING RECEIPT

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
08/957,045	10/24/97	1611	\$954.00	PB1517US3	0	(2)	(2)

5 5

DAVID J LEVY
GLAXO WELLCOME INC
FIVE MOORE DRIVE
PO BOX 13398
RESEARCH TRIANGLE PARK NC 27709

Receipt is acknowledged of this patent application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s) SUSAN MARY DALUGE, CHAPEL HILL, NC; MICHELLE JOANNE FUGGETT, ~~DURHAM, NC~~; MICHAEL TOLAR MARTIN, DURHAM, NC.

CONTINUING DATA AS CLAIMED BY APPLICANT-
THIS APPLN IS A DIV OF 08/682,743 07/31/96

FOREIGN APPLICATIONS-	PCT GREAT BRITAIN	PCTGB9500225 9402161.5	02/03/95 02/04/94
-----------------------	----------------------	---------------------------	----------------------

FOREIGN FILING LICENSE GRANTED 01/23/98
TITLE
CHLOROPYRIMIDINE INTERMEDIATES

PRELIMINARY CLASS: 544

REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.60
(Large Entity)

DOCKET NUMBER	ANTICIPATED CLASSIFICATION		PRIOR APPLICATION	ART UNIT
PB1517US3	CLASS 540	SUBCLASS	08/682,743	1202

AUG 10 1998
160
U.S. PATENT & TRADEMARK OFFICE

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

This is a request for filing continuation divisional application under 37 CFR 1.60 of pending prior application, Serial Number 08/682,743 filed on 07/31/96 and entitled:

CHLOROPYRIMIDINE INTERMEDIATES

1. Enclosed is a copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the attached papers are a true copy of the latest signed prior application, Serial Number 08/682,743, and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like are made punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issuing thereon.

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	5	- 20 =	0	x \$22.00	\$0.00
Indep. Claims	5	- 3 =	2	x \$82.00	\$164.00
Multiple Dependent Claims (check if applicable)					\$0.00
				BASIC FEE	\$790.00
				TOTAL FILING FEE	\$954.00

2. The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 07-1392. A duplicate copy of this sheet is enclosed.
3. A check in the amount of _____ is enclosed.
4. Cancel in this application original claims 1-4, 6-8 and 10-17 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
5. Amend the specification by inserting before the first line the sentence: "This application is a continuation division of application Serial Number 08/682,743 filed 7/31/96 which application is now:
 abandoned.
 pending.
 other (explain): 08/682,743 is a 371 of PCT/GB95/00225 filed 2/3/95 which claims priority from 9402161.5 filed 2/3/94.
6. Transfer the drawings from the pending prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application. (May only be used if signed by person authorized by 37 CFR 1.138 and before payment of issue fee.)

REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.60

P (Large Entity)

7. New formal drawings are enclosed.
8. Priority of foreign application number GB95/00225 & 9402161.5 filed on 2/3/95 & 2/4/94 in
PCT & GB is claimed under 35 U.S.C. 119.
Country _____
- The certified copy has been filed in prior application Serial Number 08/682,743 filed on
7/31/96



9. A preliminary amendment is enclosed.
10. The prior application is assigned of record to:
Glaxo Wellcome Inc. Assignment Recordation Date: 07/31/96 Reel/Frame: 8173/0572
Five Moore Drive
PO Box 13398
Research Triangle Park, NC 27709

11. The inventor(s) of the invention being claimed in this application is (are):
Susan M. Daluge
Michael Tolar Martin

12. This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.60(b), the Commissioner is requested to delete the name(s) of the following person or persons who are not inventors of the invention being claimed in this application:
Michelle J. F. Fugett

- 13 Also enclosed:
Information Disclosure Statement under 37 CFR 1.97

Express Mail Label No.:
EM484296011US


CERTIFICATE OF MAILING

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as express mail in an envelope addressed to :

Assistant Commissioner for Patents, Washington, D.C. 20231

Date: Oct 24 1997

By: Rosalie M. Germano
Rosalie M. GERMANO



LOGGED IN


6/12/98 KEP

CP/KLP/KC/File

COPIED TO THE UK

PTO-103X
(Rev. 8-95)

FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
08/957,045	10/24/97	1611	\$954.00	PB1517US3	0	(2)	(2)

5 5

DAVID J LEVY
GLAXO WELLCOME INC
FIVE MOORE DRIVE
PO BOX 13398
RESEARCH TRIANGLE PARK NC 27709

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

SUSAN MARY DALUGE, CHAPEL HILL, NC; MICHELLE JOANNE TUGETT, DURHAM, NC; MICHAEL TOLAR MARTIN, DURHAM, NC.

CONTINUING DATA AS CLAIMED BY APPLICANT-

THIS APPLN IS A DIV OF 08/682,743 07/31/96

FOREIGN APPLICATIONS-

PCT

GREAT BRITAIN

PCTGB9500225

02/03/95

9402161.5

02/04/95

FOREIGN FILING LICENSE GRANTED 01/23/98

TITLE

CHLOROPYRIMIDINE INTERMEDIATES

PRELIMINARY CLASS: 544